...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Open-Label Risperidone for Asperger's Disorder: Negative Symptom Spectrum Response.
【24h】

Open-Label Risperidone for Asperger's Disorder: Negative Symptom Spectrum Response.

机译：开放标签利培酮用于阿斯伯格氏症：阴性症状谱反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Asperger's disorder consists of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality disorder, and schizotypal personality disorder. We investigated whether risperidone, which is effective in treating the negative symptoms of schizophrenia, would improve such symptoms observed in Asperger's disorder in a prospective, open-label trial. METHOD: Thirteen male patients aged 6 to 18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a 12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All subjects were started on risperidone 0.25 mg twice per day. Doses were increased based on clinical indication and tolerability. The primary efficacy variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's baseline score served as his control. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale. RESULTS: We found a statistically significant improvement from baseline for last-observation-carried-forward (LOCF) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for LOCF). We also found statistically significant improvement in all secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 to < .005 for 12-week completers; F values range, 6.53 to 7.75, all p < .0001 for LOCF). CONCLUSIONS: Subjects' symptoms significantly improved after risperidone. The open-label nature of this small pilot study suggests caution in interpreting these data, but the results suggest that placebo-controlled trials should follow.
机译：目的：阿斯伯格氏病包括与精神分裂症，自闭症，精神分裂症人格障碍和精神分裂型人格障碍相似的阴性症状。在一项前瞻性，开放性试验中，我们调查了有效治疗精神分裂症阴性症状的利培酮是否会改善在阿斯伯格症中观察到的此类症状。方法：从2002年3月13日至2003年8月11日，对12名通过DSM-IV标准诊断为阿斯伯格氏病的男性患者进行了为期12周的前瞻性开放标签试验研究。每天两次使用利培酮0.25毫克开始服用。根据临床适应症和耐受性增加剂量。主要功效变量是阴性症状评估量表（SANS）。每个受试者的基线得分都作为他的对照。次要疗效指标包括阳性和阴性综合征量表，简要精神病学量表，蒙哥马利-阿斯伯格抑郁量表，总体评估量表和改良的阿斯伯格综合症诊断量表。结果：在我们的主要结局指标SANS得分（F = 13.41，对于12周完成者，p <.0001;对于LOCF，F = 9.64，p <.0001）。我们还发现所有次要功效测量均具有统计学上的显着改善（对于12周完成者，F值范围为8.41至15.73，p值范围为<.0001至<.005; F值范围为6.53至7.75，所有p <.0001对于LOCF）。结论：利培酮治疗后受试者的症状明显改善。这项小型先导研究的开放标签性质表明，在解释这些数据时应谨慎行事，但结果表明应遵循安慰剂对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号